Erratum: Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial (The Lancet (2012) 380(9838) (238–246) (S0140673612605704) (10.1016/S0140-6736(12)60570-4));Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): A prospective, randomised, open-label, blinded endpoint assessment trial

The Lancet

Volumn 380, Issue 9838, 2012, Pages 238-246

  Kirchhof, Paulus ^a,b   Andresen, Dietrich ^c   Bosch, Ralph ^d   Borggrefe, Martin ^e   Meinertz, Thomas ^f   Parade, Ulli ^g   Ravens, Ursula ^h   Samol, Alexander ^a   Steinbeck, Gerhard ^j   Treszl, Andras ⁱ   Wegscheider, Karl ^g   Breithardt, Günter ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

^d Cardiology Office Ludwigsburg   (Germany)

^e UNIVERSITY OF MANNHEIM   (Germany)

^f UNIVERSITY HEART CENTER HAMBURG   (Germany)

^g UNIVERSITY OF HAMBURG   (Germany)

^h ROBERT BOSCH HOSPITAL   (Germany)

ⁱ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^j UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLECAINIDE; ANTIARRHYTHMIC AGENT;

ADULT; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; ELECTROCARDIOGRAPHY; FEMALE; GERMANY; HEART ATRIUM FIBRILLATION; HOLTER MONITORING; HUMAN; INTERMETHOD COMPARISON; LONG TERM ANTIARRHYTHMIC DRUG TREATMENT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT TERM ANTIARRHYTHMIC DRUG TREATMENT; TELEMETRY; TREATMENT DURATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FEMALE; FLECAINIDE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864033129     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61760-7     Document Type: Erratum

References (28)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-52. (Pubitemid 28446646)
2. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003; 290: 1049-56. (Pubitemid 37430445)
3. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369-429.
4. Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002; 360: 1275-79. (Pubitemid 35284617)
5. Fetsch T, Bauer P, Engberding R, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 2004; 25: 1385-94. (Pubitemid 39078247)
6. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 2006; 166: 719-28.
7. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82: 1106-16.
8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation 1995; 92: 1954-68.
9. Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev 2011; 91: 265-325.
10. Manios EG, Kanoupakis EM, Chlouverakis GI, Kaleboubas MD, Mavrakis HE, Vardas PE. Changes in atrial electrical properties following cardioversion of chronic atrial fibrillation: relation with recurrence. Cardiovasc Res 2000; 47: 244-53. (Pubitemid 30625287)
11. Hobbs WJ, Fynn S, Todd DM, Wolfson P, Galloway M, Garratt CJ. Reversal of atrial electrical remodeling after cardioversion of persistent atrial fibrillation in humans. Circulation 2000; 101: 1145-51. (Pubitemid 30146616)
12. Kirchhof P, Engelen M, Franz M, et al. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation. Basic Res Cardiol 2005; 100: 112-20. (Pubitemid 40361603)
13. Kirchhof P, Breithardt G. New concepts for old drugs to maintain sinus rhythm in patients with atrial fibrillation. Heart Rhythm 2007; 4: 790-93. (Pubitemid 46860158)
14. Kirchhof P, Fetsch T, Hanrath P, et al. Targeted pharmacological reversal of electrical remodeling after cardioversion\rationale and design of the Flecainide Short-Long (Flec-SL) trial. Am Heart J 2005; 150: 899.
15. Kirchhof P, Nabauer M, Gerth A, et al. Impact of the type of centre on management of AF patients: surprising evidence for differences in antithrombotic therapy decisions. Thromb Haemost 2011; 105: 1010-23.
16. Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary: recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J 2007; 28: 2803-17. (Pubitemid 350135529)
17. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA 2006; 295: 1152-60. (Pubitemid 43352345)
18. Com-Nougue C, Rodary C, Patte C. How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma. Stat Med 1993; 12: 1353-64. (Pubitemid 23230837)
19. Roy D, Talajic M, Dorian P, et al, for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-20.
20. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005; 352: 1861-72.
21. Buyse M, Piedbois P. On the relationship between response to treatment and survival time. Stat Med 1996; 15: 2797-812. (Pubitemid 27011058)
22. Perneger TV, Burnand B. A simple imputation algorithm reduced missing data in SF-12 health surveys. J Clin Epidemiol 2005; 58: 142-49. (Pubitemid 40174922)
23. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-36. (Pubitemid 34778957)
24. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380-83.
25. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-77. (Pubitemid 351860859)
26. Ahmed S, Rienstra M, Crijns HJ, et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 2008; 300: 1784-92.
27. Kirchhof P, Bax J, Blomstrom-Lundquist C, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference 'research perspectives in AF'. Eur Heart J 2009; 30: 2969-77c.
28. Channer KS, Birchall A, Steeds RP, et al. A randomized placebo-controlled trial of pre-treatment and short-or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004; 25: 144-50. (Pubitemid 38112153)